News Release

Healthy cleavage: How statins protect against Alzheimer disease

Peer-Reviewed Publication

PLOS

Epidemiological studies suggest that statins, a class of cholesterol-lowering drugs, lower the risk for Alzheimer disease. How exactly statins and Alzheimer Disease are connected is not known, but a study by Sam Gandy and colleagues now suggests a possible mechanism.

Alzheimer disease is characterized by accumulation of amyloid deposits in the brain. These deposits are composed of amyloid-beta (Ab) peptide, a protein fragment that is cleaved off from the amyloid precursor protein APP. APP can be cleaved in two different ways. Amyloidogenic ("amyloid generating") cleavage by an enzyme called beta-secretase yields "sticky" (Ab) peptides that aggregate to form deposits, whereas non-amyloidogenic cleavage by alpha-secretases generates soluble peptides that do not form deposits. Studies in animal models and cell culture suggest that statins might modulate APP processing and shift the balance toward "healthy" (non-amyloidogenic) cleavage.

In their quest to understand how statins affect APP processing, Gandy and colleagues focused on a molecule called ROCK, a kinase enzyme that had recently been implicated in APP processing. Working in mouse neuroblastoma cells, they confirmed that two different statins increased healthy cleavage of APP. When they then blocked ROCK, the effects were similar to those of the statins: an increase in healthy cleavage. On the other hand, when they added a super-active version of ROCK, they saw much less healthy cleavage, and adding statins didn't improve the situation.

These findings suggest that statins influence APP processing, at least in part, by inhibiting the ROCK kinase. And independent of statins, ROCK might be a suitable target for drugs that promote healthy cleavage of APP.

###

Citation: Pedrini S, Carter T, Prendergast G, Petanceska S, Ehrlich M, et al. (2005) Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med 2 (1): e18.

CONTACT: Sam Gandy
Farber Institute
900 Walnut Street JHN467
Philadelphia, PA USA 19146
1-215-503-4200
1-215-503-4358 (fax)
samgandy@earthlink.net

PLEASE MENTION PLoS MEDICINE (www.plosmedicine.org) AS THE SOURCE FOR THESE ARTICLES. THANK YOU.

All works published in PLoS Medicine are open access. Everything is immediately available without cost to anyone, anywhere--to read, download, redistribute, include in databases, and otherwise use--subject only to the condition that the original authorship is properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.

About PLoS Medicine

PLoS Medicine is an open access, freely available international medical journal. It publishes original research that enhances our understanding of human health and disease, together with commentary and analysis of important global health issues. For more information, visit http://www.plosmedicine.org

About the Public Library of Science

The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.